Anderlecht

• Personalized medicine for advanced biliary cancer patients Recruiting
  2023-508100-38-00 5 2024-06-24 Advanced Biliary Cancer (ABC)
• A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients wit … Recruiting
  2022-502404-73-00 4 2024-06-03 Pancreatic ductal adenocarcinoma
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a … Recruiting
  2023-505436-35-00 5 2024-06-03 Untreated FLIPI 2-5 Follicular Lymphoma
• Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants with MAGE-A4 … Recruiting
  2023-508808-38-00 1 2024-05-29 Solid tumors
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom … Recruiting
  2023-507632-20-00 5 2024-05-01 Multiple Myeloma
• CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting
  2023-503317-29-00 5 2024-04-12 Metastatic renal cell carcinoma (mRCC)
• STRAtified Dosing based on Augmented renal clearance for CEFtriaxone in patients with severe community-acquired pneumonia: the STRADA-CEF tr … Recruiting
  2022-502013-28-00 6 2024-03-18 Severe Community-Acquired Pneumonia
• Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors Recruiting
  2023-506604-18-00 1 2024-02-14 Triple negative breast cancer
• A study in men with advanced prostate cancer to determine the safety and effects of a test drug (Lutetium (177Lu) rhPSMA 10.1 injection) Recruiting
  2024-511537-35-00 9 2024-02-09 Metastatic castration-resistant prostate cancer (mCRPC)
• DS-1103a Combination Therapy First-in-human (FIH) Study Recruiting
  2023-503965-48-00 1 2024-01-11 Advanced (unresectable or metastatic) human epidermal growth receptor
• A study of STX-478 alone and in combination with other anticancer drugs in participants with advanced solid tumors. Recruiting
  2023-504807-94-00 7 2023-12-26 Breast Cancer; Advanced solid tumors including but not limited to gyne
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac … Recruiting
  2022-502046-28-00 5 2023-12-22 HER2-Positive, PIK3CA Mutated, Locally Advanced or Metastatic Breast C
• Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressiv … Recruiting
  2022-502254-13-00 5 2023-12-18 Oligoprogressive metastatic castration-refractory prostate cancer
• Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects Recruiting
  2023-503661-28-00 5 2023-10-26 Hidradenitis Suppurativa
• Evaluation of the effectiveness of the reconsolidation therapy in a clinical population suffering from post-traumatic stress disorder Recruiting
  2022-500870-32-02 4 2023-10-04 Post-traumatic stress disorder
• Semaglutide for the treatment of glucose intolerance in women with prior gestational diabetes Recruiting
  2022-502082-22-00 11 2023-09-14 prediabetes
• A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematop … Recruiting
  2022-501831-18-00 4 2023-09-13 Patients with hematologic malignancies and undergoing allogenic hemato
• A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer Recruiting
  2022-501504-95-00 4 2023-06-23 Non-metastatic HER2-positive Breast Cancer
• A phase 1/2 open-label, multicenter study to assess the safety, pharmacokinetics and anti-tumor activity of GTAEXS617 in patients with advan … Recruiting
  2023-508227-13-00 7 2023-06-19 Advanced solid tumors
• Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study Recruiting
  2023-503481-23-00 5 2023-03-20 Maintenance treatment in metastatic non-squamous lung cancer
• Phase I/Ib clinical trial of PM54 in Advance Solid Tumors patients Recruiting
  2023-508644-22-00 7 2023-02-28 Advance Solid Tumors
• Preoperative treatment with mFOLFIRINOX (or Gem-Nab-P) +/- isotoxic high-dose Stereotactic Body Radiation Therapy (iHD-SBRT) for borderline … Recruiting
  2022-501181-22-01 4 2023-02-06 Pancreatic adenocarcinoma
• A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokine … Recruiting
  2023-506818-45-00 7 2022-12-13 Solid tumors that have a high incidence of Homologous Recombination (H

Showing 169–192 of 445 trials